Originally posted in Cystic Fibrosis News From Medical News Today

An international research team led by Queen’s University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the ‘Celtic Gene’, a genetic mutation which is particularly common in Ireland…

Originally posted in Cystic Fibrosis News From Medical News Today

Glasgow biopharmaceutical firm, Lamellar Biomedical Ltd, launched four years ago to develop a new class of therapies for the prevention, treatment and control of severe respiratory disease, today announced that their lead clinical candidate LMS-611 for the treatment of patients with cystic fibrosis has received Orphan Drug Designation from the European Commission…

Originally posted in Cystic Fibrosis News From Medical News Today

Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON

Originally posted in Cystic Fibrosis News From Medical News Today

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE

Originally posted in Cystic Fibrosis News From Medical News Today

Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA)…

Originally posted in Cystic Fibrosis News From Medical News Today

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF). STRIVE was designed to evaluate VX-770 among 161 people 12 years or older with a mutation known as G551D in the CF gene…

Originally posted in Cystic Fibrosis News From Medical News Today

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis. The study enrolled 62 people with two copies of the most common CF mutation, known as Delta F508. The trial lasted three weeks…

Originally posted in Cystic Fibrosis News From Medical News Today

A team of international researchers, including Case Western Reserve University School of Medicine, have discovered regions of the genome that affect the severity of the genetic disease cystic fibrosis (CF), the most common lethal genetic disease affecting children in North America…

Originally posted in Cystic Fibrosis News From Medical News Today

A team of researchers, including a number from the University of North Carolina at Chapel Hill School of Medicine, have pinpointed regions of the genome that contribute to the debilitating lung disease that is the hallmark of cystic fibrosis. Their findings provide insight into the causes of the wide variation in lung disease severity experienced by CF patients…

Originally posted in Cystic Fibrosis News From Medical News Today

Johns Hopkins Institute for Genetic Medicine researchers working as part of the North American Cystic Fibrosis Consortium have discovered two regions of the genome that affect the severity of cystic fibrosis, a genetic condition that causes scarring throughout the body, affecting most notably the pancreas and lungs…

Originally posted in Cystic Fibrosis News From Medical News Today

The Cystic Fibrosis Foundation announced today that more than 200 cities will host Great Strides walks May 21-22, 2011. Great Strides is a national fundraiser that generates critical funds for lifesaving cystic fibrosis research, education and care. The 2011 goal of Great Strides is to raise nearly $40 million nationwide. May is National Cystic Fibrosis Awareness Month…

Originally posted in Cystic Fibrosis News From Medical News Today

Scientists at Queen’s University Belfast have begun work into improving the lives of thousands of Cystic Fibrosis sufferers thanks to the award of a 1.74 million pound US-Ireland Research and Development Partnership grant…

Originally posted in Cystic Fibrosis News From Medical News Today

Mpex Pharmaceuticals, Inc. during the JP Morgan 29th Annual Healthcare Conference, announced that it has initiated its Phase 3 clinical trial program with Aeroquin™ (MP-376) for the treatment of pulmonary infections in patients with cystic fibrosis (CF)…

Originally posted in Cystic Fibrosis News From Medical News Today

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced the top-line results from its second Phase 3 clinical trial, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis (CF)…

Originally posted in Cystic Fibrosis News From Medical News Today

A team of Johns Hopkins Children’s Center researchers has discovered that a protein involved in cystic fibrosis (CF) also regulates inflammation and cell death in emphysema and may be responsible for other chronic lung diseases…

Originally posted in Cystic Fibrosis News From Medical News Today

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM)…

Originally posted in Cystic Fibrosis News From Medical News Today

Cystic fibrosis (CF) patients with normal to mildly impaired lung function may benefit from a new investigational drug designed to help prevent formation of the sticky mucus that is a hallmark of the disease, according to researchers involved in a phase 3 clinical trial of the drug…

Originally posted in Cystic Fibrosis News From Medical News Today

Like an overprotective parent on the first day of school, a targeting factor sometimes needs a little push to let go of its cargo. Scientists at the European Molecular Biology Laboratory (EMBL) in Grenoble, France, have visualised one such hand-over. They were the first to determine the structure of a ribosome-protein complex involved in carrying nascent proteins out of the cell…

Originally posted in Cystic Fibrosis News From Medical News Today

The University of British Columbia, in partnership with the Canadian Cystic Fibrosis Foundation (CCFF) and the Centre for Drug Research and Development (CDRD), has launched the Cystic Fibrosis Technology Initiative (CFTI) to advance Canadian technologies that will help combat cystic fibrosis (CF)…

Originally posted in Cystic Fibrosis News From Medical News Today

Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to a study published online in Genetics in Medicine, the official publication of the American College of Medical Genetics (ACMG)…

Advances being made in CF research have the potential to make dreams come true for people with CF that were impossible just decades ago.

The CF Foundation asked some of the many extraordinary people affected by this disease, including Members of Congress and volunteers like you, to share their dreams for the future:

One of the most important reasons Members of Congress join our fight is that they?ve heard from someone touched by CF.

Join the hundreds of Advocates who speak out for CF by becoming a part of Make Every Breath Count — the CF Foundation?s national advocacy program that helps volunteers like you meet with their Members of Congress.

Speak out, get involved, and inspire action today by signing up for Make Every Breath Count!

Just like you, Senator James Inhofe (R-OK) was inspired to take action:

?Because I have a staffer with cystic fibrosis, the challenges faced by patients with CF hit particularly close to home. As a continued supporter for medical advancements in CF, I urge patients, their families, and friends to contact their state lawmakers to ensure your voice is heard in Congress. Together, we can make a dramatic difference in the lives of those affected by this debilitating disease and make CF a thing of the past.?

Make sure your lawmakers support our fight against CF by funding innovative CF research and quickly and safely moving promising new therapies into the hands of patients. If you don?t inspire them to act, who will?

Sign up for Make Every Breath Count!

Coming Soon: New Advocacy Website

Soon, it will be easier than ever to communicate with your elected officials about issues important to people with CF. The Cystic Fibrosis Foundation will unveil a new advocacy website later this month which will provide you with:

• Faster, less complicated access to the contact information for your Members of Congress
• The ability to easily track all of your communications with elected officials
• A new tool to share your CF story with your elected officials
• A reference guide showing where your elected officials stand on issues affecting people with CF

Thank you! Together, we are making a difference for people with CF.

Sincerely,

Cystic Fibrosis Foundation
800-FIGHT-CF
info@cff.org
www.cff.org

Originally posted in Cystic Fibrosis News From Medical News Today

In a study published in this week’s New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups…

Originally posted in Cystic Fibrosis News From Medical News Today

An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients, according to findings published Nov. 18, 2010, in the New England Journal of Medicine. The investigational drug, VX-770, appeared to improve function of what is known as CFTR–the faulty protein responsible for CF…

Originally posted in Cystic Fibrosis News From Medical News Today

PTC Therapeutics, Inc. announced the publication of data from a Phase 2a clinical trial of ataluren in children with nonsense mutation cystic fibrosis (nmCF) in the American Journal of Respiratory and Critical Care Medicine…

Originally posted in Cystic Fibrosis News From Medical News Today

An imbalance of salt and water in patients with cystic fibrosis makes their lungs clog up with sticky mucus that is prone to infection. The cause of the offending imbalance is a well-known genetic error, one that blocks the molecular expressway for tiny chloride ions to move across the surface of the lungs…

Originally posted in Cystic Fibrosis News From Medical News Today

A new study using a pig model of cystic fibrosis (CF) suggests that low levels of a growth promoting hormone at or before birth may contribute to growth defects in patients with CF. The study, led by University of Iowa researchers and published online the week of Nov…

Originally posted in Cystic Fibrosis News From Medical News Today

The Cystic Fibrosis Foundation announced that it will partner with CVS/pharmacy and Warner Home Video for the second year to raise critical funds for cystic fibrosis through the sale of classic family movies this holiday season. From now through Dec…

Originally posted in Cystic Fibrosis News From Medical News Today

Pharmaceutical company Pharmaxis (ASX: PXS) announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis. The combined results have been presented for the first time at the North American Cystic Fibrosis Conference (NACFC) currently underway in Baltimore…

Originally posted in Cystic Fibrosis News From Medical News Today

Transave, Inc., reported positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections…

Originally posted in Cystic Fibrosis News From Medical News Today

In the largest meeting of its kind, nearly 4,000 doctors, scientists, researchers and caregivers will meet in Baltimore, Md., Oct. 21 – 23, 2010, to present the latest information and advancements on cystic fibrosis (CF) drug development, research and care…